Navigation Links
Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
Date:8/2/2011

ration (FDA) later this year."

For more information or to view the full abstracts, please visit the scientific presentations page located in the investors and media section on the Pacira website at www.pacira.com.

About Pacira

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postsurgical analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.

About EXPAREL™

EXPAREL is Pacira's proprietary drug candidate consisting of bupivacaine encapsulated in DepoFoam®, both of which are currently used separately in FDA-approved products. Bupivacaine is a well-characterized anesthetic/analgesic that has an established safety profile with more than 20 years of use in the United States. Market data indicate that there is an unmet medical need for a longer-acting anesthetic/analgesic for postsurgical pain management. Several Phase 2 and Phase 3 clinical trials have been completed for EXPAREL and suggest statistically significant reduction of pain in soft
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
2. Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
3. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
4. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
5. Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference
6. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
7. Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
8. Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
9. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
10. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Corporation (NYSE: CVS ) today announced that ... making a presentation to investors at the Citi Investment ... Mr. Merlo is scheduled to present at 2:10 pm ... webcast of the presentation will be broadcast simultaneously through ...
... NEW YORK, May 19, 2011 Two studies ... that an improved method for performing the standard upper endoscopy ... year increases the detection of pre-cancerous cells in the esophagus ... percent over the last 25 years, making it the fastest ...
Cached Medicine Technology:Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 2Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 3Improved Endoscopy Method Increases Detection of Esophageal Pre-Cancer by Over 40 Percent 4
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- Watching action shows ... study contends. People eat much more snack food while ... to the Cornell University researchers. "We find that if ... see more action too," study author Aner Tal, of the ... release. "In other words, the more distracting the program is, ...
(Date:9/1/2014)... 01, 2014 Currently, scientists continue ... treatments for Alzheimer's disease (AD), which reflects their ... regarding the diagnosis of the disease, especially in ... appropriate diagnostic tests. In 2014, after decades ... breakthroughs in the medicine world, there are still ...
(Date:9/1/2014)... More than 200 Lipitor lawsuit ( ... litigation that continues to progress in the U.S. District ... , A federal Case List published on August ... cholesterol medication by plaintiffs who developed Type 2 diabetes ... Inc. failed to adequately warn patients and their doctors ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... who self-paid for their antiretroviral medications experienced interruptions ... or supply logistical disruptions. These treatment interruptions led ... in patients. ,These findings by a ... Institute at Makerere University, Kampala, and UCSF are ...
... 135-2 to pass (HB 1098) a Senate-approved bill that would ... until 2011, the New York Times reports.// ,Gov. ... that mandates that all girls entering the sixth grade beginning ... the executive order will allow parents who do not want ...
... least 3 years after undergoing in vitro fertilization (IVF) ... cell// research, according to a report. ,The ... of the report, was the complete and clear explanation ... legal advisor and embryologist, which helped couples navigate the ...
... Institute is seeking to raise glaucoma awareness among Mexican-Americans,// who ... Casa Grande Valley Dispatch reports. ,Mexican-Americans over ... family history of glaucoma all face a higher risk for ... the most common form glaucoma. ,The rate ...
... music and witty tales kept Delhi audiences enthralled as spiritual ... happiness and peace. ,Far from being a moral ... Thursday on 'Circus of the mind' was a simple talk ... is a very well-coordinated activity made to look like a ...
... The amount Americans spent on arthritis medications more than ... number of people// with the disease, increases in the ... inflation-adjusted cost per prescription, according to a new study ... a six-year study of U.S. arthritis patients and the ...
Cached Medicine News:Health News:Resistance to Anti-HIV Drugs in Uganda Developed Due to Drug Supply Problems 2Health News:Many Couples Choose to Donate Surplus Embryos for Stem Cell Research 2Health News:Mind Control is the Key to Happiness: Sadguru Jaggi Vasudev 2Health News:Treatment Cost for Arthritis on the Rise: Study 2
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option....
System, English (Continental cord), 230 VAC....
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Medicine Products: